Request a Rep French Fr

Bristol-Myers Squibb
remains committed to
helping your patients
throughout their treatment journey

HCP Resources Patient Resources
OPDIVO, OPDIVO + YERVOY
Patient Alert Card

Risk Minimization Tool

DOWNLOAD
YERVOY
Patient Alert Card

Risk Minimization Tool

DOWNLOAD
OPDIVO, OPDIVO + YERVOY
Patient Information Guide

Risk Minimization Tool  

DOWNLOAD
YERVOY
Patient Information Guide

Risk Minimization Tool

DOWNLOAD
Digital Patient Information

For additional information about nivolumab side effects, have your patients connect to BMS’ risk management safety information website.

CONNECT
Other resources
to support patients on
immune-oncology therapy

Contact your BMS field representative

REQUEST A REP

Please consult the OPDIVO Product Monograph
or click here for important information relating to:

  • The most serious warnings and precautions regarding severe/fatal immune-mediated adverse reactions (imARs), allogeneic hematopoietic stem cell transplantation (HSCT), multiple myeloma and administration under the supervision of physicians experienced in the treatment of cancer.
  • Other relevant warnings and precautions regarding frequency and signs and symptoms of imARs, infusion reaction, patients on controlled sodium diet, haemophagocytic lymphohistiocytosis (HLH), pregnancy, nursing and patients with moderate or severe hepatic or severe renal impairment.
  • Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions

Please consult the YERVOY Product Monograph
or click here for important information relating to:

  • The most serious warnings and precautions regarding severe/fatal immune-mediated adverse reactions (imARs) and administration under the supervision of physicians experienced in the treatment of cancer.
  • Other relevant warnings and precautions regarding frequency and signs and symptoms of imARs, patients who have had a severe or life-threatening skin adverse reaction on a prior cancer immune stimulatory therapy, haemophagocytic lymphohistiocytosis (HLH), Vogt-Koyanagi-Harada syndrome, serous retinal detachment, Graft-versus-host disease (GVHD), solid organ transplant rejection in the post-market setting, patients on immunosuppressive therapy for life-threatening disease or condition, autoimmune hemolytic anemia, myotoxicity (myositis, myocarditis, and rhabdomyolysis), patients on controlled sodium diet, concurrent administration with vemurafenib, patient counseling information: imARs and fatigue, hepatic impairment, renal impairment, pregnancy, nursing women and required close monitoring.
  • Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions